Table 2.
Clinical characteristics of human optic nerve samples.
| Reference | Code | Gender | Age | PMD (hours) | Duration of MS (years) | MS type | Optic Nerve Alterations |
|---|---|---|---|---|---|---|---|
| MS Samples | |||||||
| MS1 | 98-176 | M | 83 | 7:05 | 52 | PP | No |
| MS2 | 99-054 | F | 58 | 8:10 | 20 | SP | Yes |
| MS3 | 98-185 | F | 70 | 8:55 | 19 | PP | Yes |
| MS4 | 98-158 | F | 76 | 16:31 | 53 | SP | Yes |
| MS5 | 98-087 | F | 55 | 7:35 | > 11 | SP | No |
| MS6 | 98-179 | F | 60 | 8:50 | 36 | PP | Yes |
| MS7 | 99-062 | F | 79 | 10:00 | 44 | PP | No |
| MS8 | 99-025 | F | 64 | 7:45 | 35 | SP | Yes |
| MS9 | 98-066 | F | 75 | 4:50 | > 27 | PP/SP | No |
| MS10 | 01-018 | F | 48 | 8:10 | 8 | SP | No |
| MS11 | 01-003 | M | 69 | 10:00 | 34 | PP | Yes |
| MS12 | 99-119 | F | 38 | 5:15 | 10 | RR | No |
| MS13 | 00-024 | F | 52 | 8:25 | 16 | PP/SP | Yes |
| MS14* | 99-109 | M | 70 | 6:25 | 22 | SP | Yes |
| MS15* | 99-121 | M | 51 | 7:50 | 29 | SP | Yes |
| MS16* | 99-066 | M | 69 | 16:45 | 46 | PP | No |
| Control Samples | |||||||
| C1, 14,16 | 98-101 | M | 72 | 6:45 | |||
| C2,5 | 98-125 | F | 58 | 6.15 | |||
| C3 | 98-104 | F | 74 | 7:25 | |||
| C4 | 98-051 | F | 94 | 16:50 | |||
| C6 | 98-061 | F | 64 | 6:00 | |||
| C7 | 98-042 | F | 79 | 9:45 | |||
| C8 | 98-148 | F | 54 | 5:35 | |||
| C9 | 98-112 | F | 84 | 9:20 | |||
| C10, 13 | 00-050 | F | 52 | 6:50 | |||
| C11 | 00-090 | M | 70 | 7:45 | |||
| C12 | 00-025 | F | 41 | 13:30 | |||
| C15 | 98-127 | M | 56 | 5:25 |
Optic nerve alterations consisted of macroscopic plaques, atrophy and/or optic neuritis.
Abbreviations: Reference, Netherlands Brain Bank bar-coded numbers; A, microarrays; qPCR, real-time quantitative PCR; IH, immunohistochemistry; C, control; MS, multiple sclerosis; M, male; F, female; PMD, postmortem delay; PP, primary progressive; SP, secondary progressive; RR, relapsing remitting. * These samples have been used only for immunohistrochemistry